Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2014-04-09 AGM Information
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
AGM Information Classification · 1% confidence The document is titled "Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma" (Shareholders in Karolinska Development AB (publ) are summoned to the Annual General Meeting). It details the date, location, registration procedures, and a full proposed agenda for a general meeting. The agenda includes items typical for an AGM, such as electing the chairman, approving the annual report (Item 7), deciding on profit distribution (Item 10), approving remuneration guidelines (Item 16), and proposing a performance-related stock program (Item 17). The content is clearly a formal notice and materials related to convening an Annual General Meeting (Årsstämma). This directly corresponds to the definition of AGM Information.
2014-04-09 Swedish
Nya studiedata pekar på att SHACT kan underlätta för kvinnor som genomgår hysteroskopi
Regulatory Filings Classification · 1% confidence The document is a press release dated March 25, 2014, announcing positive results from a clinical study regarding the product SHACT for use during hysteroscopy. It details study objectives, results, and includes quotes from management and an external expert. This format—a news announcement detailing recent operational or clinical progress, often including financial context (like ownership percentages) but not being a full periodic report (10-K, IR) or a formal regulatory filing notification—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on study results and product development rather than just quarterly financial figures, it aligns best with the general category of an initial announcement of results/developments. Given the options, 'Earnings Release' (ER) is the closest fit for a press release announcing key operational/clinical milestones, although 'Regulatory Filing' (RNS) could be a fallback if the content was purely administrative. However, the content is substantive news about a clinical trial outcome, making ER the most appropriate classification for a company reporting key progress outside of a mandatory periodic filing.
2014-03-25 Swedish
New trial data suggest that SHACT could benefit women undergoing hysteroscopies
Regulatory Filings Classification · 1% confidence The document is a press release dated March 25, 2014, announcing positive results from a feasibility study regarding a local anesthetic agent (SHACT) for hysteroscopy. It details study objectives, results (safety, tolerability, feasibility), and includes quotes from the CEOs of Pharmanest AB and Karolinska Development, as well as a doctor. This content structure—announcing new data/results for a specific product/indication—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing announcement (RPA/RNS), and it focuses purely on operational/clinical progress, it best fits the 'Earnings Release' category, which often includes operational highlights and clinical updates, even if it's not tied to a formal quarterly earnings period. Given the options, ER is the closest fit for a significant operational/clinical update announcement.
2014-03-25 English
Dilafor enters into a license and partnership agreement with Lee’s Pharmaceutical
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific business event: a license and partnership agreement between Dilafor AB and Lee's Pharmaceutical Holdings Ltd regarding the drug tafoxiparin. This type of announcement, detailing strategic business development, licensing deals, and associated financial terms (upfront payments, milestones, royalties), is characteristic of corporate news releases that often precede formal regulatory filings or are used for immediate market communication. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a proxy statement (DEF 14A). Since it details a significant transaction and partnership, it fits best under the general category of corporate activity announcements. Given the options, it is a specific corporate announcement that doesn't perfectly align with the highly specific categories like DIRS, DIV, or DLST. It is a significant business development announcement. While it could potentially be classified as RNS (Regulatory Filings) as a fallback, the content strongly suggests a strategic business development update. However, none of the provided codes explicitly cover 'Merger/Acquisition/Partnership Announcement' except TAR (M&A Activity), which is usually for takeovers/mergers, not licensing. Since this is a detailed announcement of a major commercial agreement, and not a short notice about a report being published (RPA), the most appropriate classification among the specific options is difficult. Given the context of financial reporting databases, major partnership/licensing deals are often grouped with M&A or treated as significant corporate news. Since TAR is for M&A/Takeover, and this is a licensing deal, I will default to the general regulatory announcement category (RNS) as it is a formal press release detailing a material event, or consider if it implies a capital change (CAP), which it does not directly. Since it is a formal announcement of a material event, RNS is the safest general classification if a specific 'Partnership' code is missing. However, if we interpret 'M&A Activity' (TAR) broadly to include significant strategic transactions like exclusive licensing agreements that involve future revenue streams and development rights, TAR might be considered. Given the strong focus on licensing and commercialization rights, and the lack of a dedicated 'Partnership' code, RNS (Regulatory Filings/General Announcement) is the most neutral and accurate fit for a press release detailing a licensing deal that isn't a merger or takeover.
2014-02-20 English
Dilafor ingår licens- och partnerskapsavtal med Lee’s Pharmaceutical
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a licensing and partnership agreement between Dilafor AB and Lee's Pharmaceutical Holdings Ltd regarding the drug tafoxiparin for specific indications in China and surrounding territories. This type of announcement details a significant business transaction, often involving future payments, royalties, and joint development plans. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific corporate action announcement. Since there is no specific category for 'Licensing Agreement' or 'Partnership Announcement', the most appropriate category is 'Regulatory Filings' (RNS) as a general announcement of material corporate news that doesn't fit the other specific categories, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on the financial structure change, but the core is the business deal itself. Given the nature of the announcement (a material business development/transaction), RNS is the best fit as a general regulatory disclosure, although 'TAR' (M&A Activity) is for mergers/takeovers, which this is not. I will classify it as RNS as it is a general corporate announcement.
2014-02-20 Swedish
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Bokslutskommuniké januari – december 2013' (Year-end report January–December 2013) for Karolinska Development AB. It contains comprehensive financial data, including income statements, balance sheets, and key performance indicators for the full fiscal year 2013. It also includes detailed management commentary on business progress, portfolio developments, and clinical trial results. As it provides substantive financial statements and analysis for a period shorter than a full annual report (or as a year-end interim report), it is classified as an Interim/Quarterly Report. FY 2013
2014-02-19 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.